Camallergy awarded £1.1m government funding for peanut allergy immunotherapy

pharmafile | March 9, 2021 | News story | Manufacturing and Production Camallergy, UK, allergy 

Camallergy, a biopharmaceutical company dedicated to providing innovative, patient-centric treatments for life-threatening food allergies, today announced it has been awarded £1.1 million funding under the Innovate UK Biomedical Catalyst Award programme.

The programme is administered by Innovate UK, the UK’s research and innovation agency.

Camallergy’s lead product, CA002, is a second-generation novel oral immunotherapy for the treatment of peanut allergy, designed to offer ‘bite-proof’ protection to patients within 14 weeks of therapy.

The £1.1 million in non-dilutive funding will be used to accelerate the company’s peanut allergy immunotherapy for planned Phase III clinical trials.

The project commences in the first quarter of 2021, and as part of the project’s success, the company intends to file its investigational new drug application with the FDA, as well as submit a clinical trials application to the MHRA and EMA.

Dr Sarah Oakley-Mudge, Director of Clinical Development at Camallergy, said: “This innovation award is further testament to Camallergy’s leadership and capabilities in the field of peanut allergy immunotherapy.

“With the only cGMP-certified manufacturing facility in Europe dedicated to producing peanut allergy immunotherapy for human use, we believe we are well positioned to utilise this award to accelerate the development of CA002 into Phase III trials and towards commercialisation”.

Darcy Jimenez

Related Content

FDA advisory committee votes in support of favourable benefit-risk profile for ARS Pharmaceuticals’ allergic reaction treatment

US-based biopharmaceutical company ARS Pharmaceuticals has announced that the US Food and Drug Administration (FDA)’s …


Long COVID: 15 studies launched with £19.6 million government funding

The UK government has announced the launch of 15 new extensive studies, backed by £19.6 …

Drugmakers fined a record £260 million after 10,000% drug price increase

The UK’s competition authority has issued its largest ever fine of more than £260 million …

Latest content